Navigation Links
Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017
Date:2/21/2017

ROCKVILLE, Md., Feb. 21, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for the year ended December 31, 2016 on Thursday, March 2, 2017, and to host a conference call the same day at 4:30 p.m. EST. The dial-in information for the call is as follows:

U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/19873. An archived replay of the call will be available for approximately ninety (90) days at the same URL, https://www.webcaster4.com/Webcast/Page/1096/19873 beginning approximately one hour after the call's conclusion.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD) and the emergence of antimicrobial-resistance (AMR). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.   

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-2016-year-end-operational-highlights-and-financial-results-on-march-2-2017-300410841.html


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Synthetic Biology: Global Markets - Research and Markets
2. Synthetic Biologics to Present at the 2017 BIO CEO & Investor Conference
3. Ginkgo Bioworks Acquires Leading Synthetic DNA Provider Gen9
4. Synthetic Genomics Appoints Tina Nova, Ph.D., and William McKee to Board of Directors
5. Teewinot Life Sciences Corporation Licenses Biosynthetic Technology to AMRI for the Production and Sale of the First Commercially Available CBCA Analytical Standard
6. Synthetic Biologics Reports 2015 Year End Operational Highlights and Financial Results
7. Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea
8. Synthetic Biologics to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
9. Soligenix Announces Initiation of its Pivotal Phase 3 Clinical Trial of SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma
10. Synthetic Biologics to Webcast Microbiome Clinical Program Seminar
11. Global Synthetic Biology Market Expected to Grow With 35% CAGR During 2015 - 2020: P&S Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2019)... ... , ... The American Society of Gene & Cell Therapy (ASGCT) is proud ... initiative for 2019. Designed by ASGCT committee volunteers in coordination with patient advocacy groups, ... public on the status and promise of gene and cell therapies. , Gene ...
(Date:1/11/2019)... ... January 11, 2019 , ... Boekel Scientific launches its ... donor blood. This advanced and intuitive medical device was designed in conjunction ... needed for the busiest donor stations with new-to-the industry features to improve efficiency ...
(Date:1/8/2019)... ... 07, 2019 , ... Today AngelMD announced that it completed ... investment AngelMD has made into Noninvasix in the past year. , To reduce ... to directly, accurately, and noninvasively measure brain oxygenation in preterm babies in the ...
(Date:1/4/2019)... ... January 02, 2019 , ... CellMax Life ... cells in blood, has been named as a partner in Medigen Biotech’s upcoming ... cell therapies for cancer treatment, will use CellMax Life’s circulating tumor cell platform ...
Breaking Biology Technology:
(Date:1/5/2019)... ... January 04, 2019 , ... Join Bill Fox, Chief Strategy ... Sciences from MarkLogic – for a live webinar on Wednesday, January ... of using real world data for pharmacovigilance, and the implications of current inefficient ...
(Date:12/27/2018)... ... 27, 2018 , ... uBiome, the leader in microbial genomics, ... Morgan 37th Annual Healthcare Conference in San Francisco, which brings together industry leaders, ... , Since its origin in 1983, the JP Morgan Healthcare Conference has ...
(Date:12/19/2018)... ... December 19, 2018 , ... InTouchMD’s flagship product, ... in healthcare for 2018. , PM360 is featuring the recognition in its 7th ... and services offered to the pharmaceutical and medical device industries. , “This recognition comes ...
Breaking Biology News(10 mins):